HomeBlog Details

blog
Meticulous Research®

The name of our company defines our services, strengths, and values. Since the inception, we have endeavoured to research, analyze and present the critical market data with great attention to details.

Technological Advancements in Bioprocessing Driving the Demand for Biopharmaceutical Equipment and Consumables

   August 14, 2024

Biopharmaceuticals are complex medicines composed of living organisms and produced utilizing cutting-edge biotechnological processes. Biopharmaceuticals are increasingly being used to treat a wide range of disorders in order to lower the risk of treatment-related toxicity while also maximizing therapeutic effectiveness. With the growing relevance of biopharmaceuticals, more companies are focusing on their research and manufacturing, raising the demand for biopharmaceutical consumables and equipment. Recent technological improvements in equipment are assisting corporations in reducing the manufacturing challenges associated with biopharmaceuticals, thereby enhancing utilization.

Monoclonal Antibody Production: Largest Application Area for Biopharmaceutical Equipment and Consumables

A monoclonal antibody (mAb) is a protein created by cell division from a single ancestral cell. It exerts a therapeutic impact by targeting certain receptors or other proteins (antigens) on the surface of normal or malignant cells. Owing to their high target specificity, mAbs are being manufactured more frequently annually, which allows for effective medical therapy. Therapeutic antibodies are becoming increasingly important in drug research and development processes. As therapeutic monoclonal antibodies become increasingly widely approved, there are huge opportunities for continuous bioprocessing manufacturing.

In 2023, the U.S. FDA approved 12 therapeutic antibodies, including notable monoclonal antibodies such as Pozelimab (VEOPOZ) and Elranatamab (Elrexfio). Several additional monoclonal antibodies are currently undergoing review by the U.S. FDA and European Union regulatory authorities. Upon approval, these antibodies will proceed to production, thereby driving increased demand for the necessary equipment and consumables required for their commercial manufacturing and processing.

Additionally, Amgen Inc. (U.S.) and UCB (Belgium) are jointly developing a biologic named EVENITY, which is intended for the treatment of osteoporosis in postmenopausal women. This development is managed by Amgen Astellas BioPharma K.K. (Japan), a joint venture between Amgen Inc. and Astellas Pharma Inc.

Use of Single-use Bioreactors is Expected to Gain Traction in the Market

Single-use bioreactors, also known as disposable bioreactors, use a disposable bag instead of a culture vessel. They are widely employed in mammalian cell culture and are quickly replacing traditional bioreactors. Instead of a stainless steel or glass culture vessel, single-use bioreactors employ a disposable bag. This brings various advantages to single-use bioreactors. The versatility provided by single-use bioreactors allows biopharmaceutical companies to manufacture multiple medications in a single facility. This saves time and money while maintaining the quality of each medicine.

Additionally, single-use bioreactors eliminate the need for expensive and large clean-in-place (CIP) or steam-in-place (SIP) systems, which are required for reusable bioreactors. Thus, the benefits of single-use bioreactors and their wide range of applications in cultivating human cells, insect cells, and other cell types with minimal oxygen requirements are driving the segment's growth. Furthermore, single-use bioreactors are thought to be clean, safe, and easy since they decrease the chance of batch-to-batch microbial contamination. Single-use bioreactors reduce the need to clean, assemble, leak test, and sterilize individual bioreactor components, potentially saving time.

Insights from Biopharmaceutical Processing Equipment and Consumables Market Analysis

Recent insights from Meticulous Research® provide valuable perspectives on the future trajectory of the biopharmaceutical processing equipment and consumables market. Projections suggest a potential worth of $75.72 billion by 2031, driven by a remarkable Compound Annual Growth Rate (CAGR) of 9.5% from 2024 to 2031.

As the global landscape takes shape, Europe is expected to hold a substantial market share in 2024. This regional share is attributed to the significant and rapidly evolving biopharmaceutical industry in the region and support from government and regulatory authorities to promote the use of biopharmaceuticals for various health indications.

In Europe, various companies are expanding their manufacturing capacities as well as their operations, leading to the widespread adoption of the products. This comprehensive overview from Meticulous Research serves as a gateway into the biopharmaceutical processing equipment and consumables market.

Conclusion

The growing biopharmaceuticals market is driving growth in biopharmaceutical processing equipment, consumables, and plant capacity expansions, along with increased adoption of single-use bioprocessing equipment. However, the complexity of biopharmaceutical development and manufacturing limits market growth. Opportunities are emerging due to rising demand in developing economies, the shift to Bioprocessing 4.0, and the growing trend of personalized medicines. However, high capital requirements for production remain a significant challenge. To conclude, while the market has strong growth prospects, overcoming production complexities and capital constraints remains a major challenge for players operating in this market.

Access Full Report Here @  https://www.meticulousresearch.com/product/biopharmaceutical-processing-equipment-and-consumables-market-4200


Related Tag:

Related Blogs:
  Download Free Sample Report